N/A N=428 A Randomized Controlled Trial of Mental Health Peer-Led Education
Mental Disorders
Primary: Recovery From Mental Illness — 91.90; 90.72; 94.84; 91.01 score on a scale — p=.013
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=554 Communicating Multiple Disease Risks: A Translation of Risk Prediction Science
Healthy Volunteers
Primary: Change From Baseline to 90-day Follow-up in Self Reported Weekly Minutes of Exercise — 92.2; 37.5; 63.1; 60.0 minutes — p=0.0288
N/A N=28 Hyper-Arousal in Chronic Primary Insomnia
Chronic Insomnia
Primary: Sympathetic Baroreflex Sensitivity (BRS) Unit — -2.1; -4.3 bursts per 100 heart beats per mm Hg
Phase 3 N=135 A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
Pemphigus Vulgaris
Primary: Percentage of Participants (Excluding Telemedicine [TM] Participants) Who Achieved Sustained Complete Remission, Evaluated by the Pemphigus Disease Area Index (PDAI)…
N/A N=306 Virtual vs. Traditional Physical Therapy Following Total Knee Replacement
Total Knee Replacement
Primary: Cost Difference in US Dollars — 1050.00; 2805.00 US Dollars
Phase 2 N=346 Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women
PNC Vaccine · HIV-infected Pregnant Women
Primary: Number of Women Who Experienced Various Adverse Events (AEs) — 2; 3; 4; 1 Participants
N/A N=63 Adherence in Pediatric Multiple Sclerosis
Multiple Sclerosis
Primary: Change in Level of Adherence in Subjects (Objective Measure) — 0.95; 0.86; 0.85; 0.81 Proportion of doses (actual vs expected)
Phase 1 N=24 Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
Hepatic Impairment
Primary: Cmax: Maximum Plasma Concentration of Lemborexant — 62.9; 48.7; 39.8 nanogram per milliliter (ng/mL)
N/A N=31 Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD
ADHD
Primary: Change in CANTAB ADHD Battery - Motor Control Task — -0.033; -0.067 reaction time (ms)
Phase 1 N=56 Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea
Obstructive Sleep Apnea · Healthy Subjects
Primary: HV Cohort: Peripheral Oxygen Saturation (SpO2) During Total Sleep Time (TST) on Day 1 of Treatment — 95.34; 95.00; 95.07 percentage of oxygen saturation — p=0.099
N/A N=111 A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Clinical Benefit — 53; 20; 5; 7 Participants
Phase 3 N=660 A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) — 4.8; 11.4; 16.8…
Early Phase 1 N=18 Safety and Pharmacokinetics of an Extract of Naringenin
Safety Issues · Pharmacokinetics
Primary: Incidence of Treatment-emergent Adverse Events Following a Single Dose of a Citrus Extract of Naringenin — 1; 2; 0; 1 Participants
Phase 3 N=175 A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain
Acute Pain
Primary: For the US FDA: The Total Amount of Supplemental Opioid Analgesic Medication Used Within the First 12 Hours After First Intake of Investigational Medicinal Product (IMP)…
Phase 3 N=199 Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Change From Baseline in Clinician-Administered Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Preschool Version Total Score at Week 6 — -9.1…